What's new — Hypertensive heart disease¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 10 |
| last 3 months | 10 |
| last 6 months | 13 |
| last year | 21 |
| older than a year | 231 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-08-03 | Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II): a prospective, multicentre, observational cohort study — Lancet ([PMID 42669305](https://pubmed.ncbi.nlm.nih.gov/42669305/){target="_blank" rel="noopener"}) | epidemiology-and-burden, heart-failure-management |
| 2026-08-03 | Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials — Eur J Heart Fail ([PMID 42669134](https://pubmed.ncbi.nlm.nih.gov/42669134/){target="_blank" rel="noopener"}) | diastolic-dysfunction-and-hfpef |
| 2026-08-02 | Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial — Circulation ([PMID 42666029](https://pubmed.ncbi.nlm.nih.gov/42666029/){target="_blank" rel="noopener"}) | lifestyle-and-population-prevention |
| 2026-08-02 | Hypertensive crisis in the elderly: epidemiological, clinical and outcome: EDEN-47 study — Gerontology ([PMID 42664163](https://pubmed.ncbi.nlm.nih.gov/42664163/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-08-02 | Non-linear associations between blood pressure and clinical outcomes in atrial fibrillation: A systematic review and dose-response meta-analysis — Europace ([PMID 42663497](https://pubmed.ncbi.nlm.nih.gov/42663497/){target="_blank" rel="noopener"}) | arrhythmia-and-atrial-remodeling |
| 2026-08-02 | Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy — JAMA ([PMID 42663420](https://pubmed.ncbi.nlm.nih.gov/42663420/){target="_blank" rel="noopener"}) | diagnosis-and-phenotyping |
| 2026-08-02 | Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study — Eur Heart J ([PMID 42663089](https://pubmed.ncbi.nlm.nih.gov/42663089/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-markers |
| 2026-08-02 | 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA) — Eur Heart J ([PMID 42661426](https://pubmed.ncbi.nlm.nih.gov/42661426/){target="_blank" rel="noopener"}) | guidelines |
| 2026-08-02 | 2026 ESC Guidelines for the management of heart failure — Eur Heart J ([PMID 42661420](https://pubmed.ncbi.nlm.nih.gov/42661420/){target="_blank" rel="noopener"}) | guidelines, heart-failure-management |
| 2026-08-02 | Achieved home systolic blood pressure and cardiovascular risk in older hypertensive patients — Hypertens Res ([PMID 42660976](https://pubmed.ncbi.nlm.nih.gov/42660976/){target="_blank" rel="noopener"}) | blood-pressure-targets |
| 2026-06-01 | Qualitative insights into the experiences and goals of people living with severe difficult-to-treat hypertension in Australia — BMC Cardiovasc Disord ([PMID 42321603](https://pubmed.ncbi.nlm.nih.gov/42321603/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-05-01 | Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications — Catheter Cardiovasc Interv ([PMID 42144689](https://pubmed.ncbi.nlm.nih.gov/42144689/){target="_blank" rel="noopener"}) | overview |
| 2026-04-01 | Cardiac magnetic resonance assessment of left ventricular phenotypes and prognostic implications in hypertensive heart disease — Clin Hypertens ([PMID 41953289](https://pubmed.ncbi.nlm.nih.gov/41953289/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-markers, diagnosis-and-phenotyping, outcomes-and-risk-stratification, overview |
| 2026-03-01 | Updates in the 2025 AHA/ACC Hypertension Guideline — Curr Hypertens Rep ([PMID 41843050](https://pubmed.ncbi.nlm.nih.gov/41843050/){target="_blank" rel="noopener"}) | guidelines |
| 2026-01-08 | Role of natriuretic peptides and cardiac troponins in staging hypertensive heart disease: the REMODEL study — Eur J Heart Fail ([PMID 41771092](https://pubmed.ncbi.nlm.nih.gov/41771092/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-markers, clinical-trials-landscape, diagnosis-and-phenotyping, guidelines, heart-failure-management, outcomes-and-risk-stratification, overview, patient-experience-and-advocacy |
| 2026-01-05 | Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment — Eur Heart J ([PMID 40892534](https://pubmed.ncbi.nlm.nih.gov/40892534/){target="_blank" rel="noopener"}) | diastolic-dysfunction-and-hfpef |
| 2025-12-05 | Systematic analysis of global ischemic heart disease and hypertensive heart disease burden, 1990-2021: projections to 2050 — BMC Public Health ([PMID 41350658](https://pubmed.ncbi.nlm.nih.gov/41350658/){target="_blank" rel="noopener"}) | epidemiology-and-burden, nosology-and-attribution |
| 2025-12-01 | A scoping review of qualitative studies examining the factors influencing hypertension treatment adherence in East Africa — J Biosoc Sci ([PMID 41414744](https://pubmed.ncbi.nlm.nih.gov/41414744/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-11-02 | Access to hypertension services and health-seeking experiences in rural Coastal Kenya: A qualitative study — PLOS Glob Public Health ([PMID 41270024](https://pubmed.ncbi.nlm.nih.gov/41270024/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-10-01 | Cultural and Contextual Barriers to Sustained Home Blood Pressure Monitoring Practices Among Indigenous People in Northern Thailand: A Qualitative Study — Int J Community Based Nurs Midwifery ([PMID 41189998](https://pubmed.ncbi.nlm.nih.gov/41189998/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2025-10-01 | Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 — Lancet ([PMID 41092928](https://pubmed.ncbi.nlm.nih.gov/41092928/){target="_blank" rel="noopener"}) | epidemiology-and-burden, nosology-and-attribution |
Trials — what has moved¶
23 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 0 |
| trial records updated in the last month | 2 |
| trial records updated in the last 2 months | 2 |
| trial records updated in the last 3 months | 4 |
| trial records updated in the last 6 months | 7 |
| trial records updated in the last year | 8 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2024-06-28 | A Study of the ReCor Medical Paradise System in Clinical Hypertension | NA | 282 | Solo Cohort - Mean Difference in Average Daytime Ambulatory Systolic B | 24 | 209 | 2 |
| 2021-05-27 | SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study | NA | 366 | Number of Participants With Major Adverse Events (MAE) Defined as a Co | 74 | 304 | 3 |
10 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| diastolic-dysfunction-and-hfpef | 2026-08-03 | 2 | 26 |
| epidemiology-and-burden | 2026-08-03 | 3 | 26 |
| heart-failure-management | 2026-08-03 | 3 | 27 |
| arrhythmia-and-atrial-remodeling | 2026-08-02 | 1 | 26 |
| biomarkers-and-imaging-markers | 2026-08-02 | 3 | 26 |
| blood-pressure-targets | 2026-08-02 | 1 | 26 |
| diagnosis-and-phenotyping | 2026-08-02 | 3 | 26 |
| guidelines | 2026-08-02 | 4 | 28 |
| lifestyle-and-population-prevention | 2026-08-02 | 1 | 29 |
| red-flags-and-safety-concerns | 2026-08-02 | 1 | 27 |
| patient-experience-and-advocacy | 2026-06-01 | 5 | 26 |
| overview | 2026-05-01 | 3 | 38 |
| outcomes-and-risk-stratification | 2026-04-01 | 2 | 25 |
| clinical-trials-landscape | 2026-01-08 | 1 | 25 |
| nosology-and-attribution | 2025-12-05 | 2 | 25 |
| ventricular-remodeling | 2025-09-01 | 0 | 25 |
| secondary-hypertension-and-modifiers | 2025-08-07 | 0 | 26 |
| pharmacologic-prevention-and-regression | 2025-08-01 | 0 | 27 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.